New Technology– category –
-
Caltech Unveils ‘BrainCAB’ Molecular Shuttle for Enhanced Blood-Brain Barrier Drug Delivery Targeting Carbonic Anhydrase IV
Caltech News USA Overview Caltech researchers have developed 'BrainCAB,' a novel molecular shuttle that efficiently crosses the blood-brain barrier (BBB) to deliver drugs to the brain. This technology utilizes a small molecule shuttle th... -
A*STAR Successfully Identifies Bispecific Antibody Stability Risks: Enhancing Manufacturability and Robustness of Next-Gen Biologics
A*STAR Singapore Overview Researchers at A*STAR's Bioprocessing Technology Institute (BTI) in Singapore have successfully identified 'labile regions' within bispecific antibodies (BsAbs) that compromise their manufacturing and stability.... -
GLP-1 Receptor Agonist Mechanism of Action: A Comprehensive Approach to Glycemic Control, Weight Loss, and Metabolic Health
(Document via Google Search) Overview GLP-1 Receptor Agonists (GLP-1 RAs) are a class of drugs that mimic incretin action to manage blood sugar and promote weight loss. They stimulate insulin secretion, suppress glucagon production, and ... -
Scientists Discover POLDIP2 as ‘Molecular Glue’ Controlling Heme, Unlocking Insights for Rare Disease Treatment
YouTube (The Deep Dive Lab) USA Overview Scientists have discovered a novel 'molecular glue' controlling heme production, the essential oxygen-carrying molecule. The mitochondrial protein POLDIP2 utilizes heme as a molecular glue to bind... -
FDA Grants Fast Track Designation to Erasca’s Oral Pan-RAS Molecular Glue ERAS-0015 for Metastatic Pancreatic Adenocarcinoma
OncLive USA Overview Erasca's oral pan-RAS molecular glue, ERAS-0015, has received FDA Fast Track Designation for metastatic pancreatic adenocarcinoma. The drug demonstrated promising initial activity in a Phase 1 study for KRAS G12-muta... -
New Blood-Brain Barrier Penetration Strategies: Peptides and ‘Trojan Horse’ Approaches Revolutionize Brain Drug Delivery
Facebook USA Overview The blood-brain barrier (BBB) blocks approximately 95% of drugs, severely impeding treatment for brain disorders. Researchers are developing novel techniques to bypass this barrier, including 'Trojan horse' approach... -
Northeastern Graduate Research Highlights Limits of AI in Drug Discovery: Human Expertise Remains Crucial for Complex Research
Northeastern University USA Overview Northeastern University graduate students examined claims that AI would completely transform drug discovery, concluding that while useful for simple tasks, AI still generates inaccurate results in com... -
Antibody-Drug Conjugate (ADC) Development Guide: Precise Design of Monoclonal Antibodies, Linkers, and Payloads is Key
Allucent USA Overview Antibody-Drug Conjugates (ADCs) combine three engineered components—a tumor-targeting monoclonal antibody, a chemical linker, and an active payload—to deliver potent cancer therapy. Upon binding to the target, ADCs ... -
Johns Hopkins’ N4-Acetylcytidine (ac4C) mRNA Platform Boosts Therapeutic Protein Production Beyond Industry Standard
Johns Hopkins Medicine USA Overview Scientists at Johns Hopkins Medicine have reported an experimental N4-acetylcytidine (ac4C) mRNA platform capable of delivering next-generation mRNA therapeutics for infectious diseases, cancer, and au... -
AI Transforms Drug Discovery: Machine Learning Drastically Cuts Costs & Timelines, Yields 75 Clinical Candidates
Facebook USA Overview AI is accelerating drug discovery and significantly reducing costs by leveraging machine learning to design candidate molecules and drastically narrow the vast protein structure search space. Algorithms like generat...
